{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:10:01Z","timestamp":1778868601493,"version":"3.51.4"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"International AIDS Society - Collaborative Initiative for Paediatric HIV Education and Research","award":["0323"],"award-info":[{"award-number":["0323"]}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Long-acting injectable antiretroviral therapy (LAI-ART) has the potential to transform HIV treatment for adolescents with perinatal HIV infection (APHI). Given the existing knowledge gaps surrounding this recent strategy, we aimed to assess interest in LAI-ART among ART-experienced APHI in Cameroon. We conducted a cross-sectional study among ART-experienced APHI aged 10\u201319 years, across four paediatric HIV clinics in the Centre region of Cameroon. Data were collected from 4 to 30 November 2024 using structured questionnaires to assess sociodemographic characteristics, awareness of, and interest in LAI-ART. HIV-1 viral load (VL) and CD4 cell counts were measured during the same period. Logistic regression analysis was used to identify factors associated with interest in switching to LAI-ART. Of 248 participants (48.8% female; median [IQR] age 15 [13\u201317]), 40.0% lived with a guardian and 75.8% had partial\/full HIV-disclosure; 3.2% reported stigma. Clinically, 77.5% were in multi-month ARV-dispensation (MDSD) and 28.2% had poor ART-adherence; fear of injection was none\/moderate\/high in 73.4%, 15.7% and 10.9%, respectively. Viral undetectability (VL\u2009&lt;\u200950 copies\/mL) and CD4\u2009\u2265\u2009500 cells\/mm\u00b3 were 71.6% and 72.5%, respectively. Overall, 92.3% expressed interest in LAI-ART, motivated by reduced pill burden\/fatigue (63.7%) and expected better adherence (74.2%); 30.2% reported prior LAI-ART awareness. In multivariable analysis, no prior awareness had 81% lower odds of interest (p\u2009=\u20090.036). Compared with no-fear, moderate-fear was associated with 46% lower odds (p\u2009=\u20090.393), while high-fear was associated with 78% lower odds (p\u2009=\u20090.017). Disparities in sex, education, residence, adherence, virological response, or treatment history did not influence interest in LAI-ART. Among all respondents, 77.1% said they would choose LAI-ART if available, whereas 20.2% preferred MDSD. In this Cameroonian APHI cohort, awareness of LAI-ART was low despite high-interest once adolescents were informed. Rollout in low\/middle-income countries should prioritise targeted education, youth-friendly counselling to close knowledge gaps, reduce fear and ensure equitable uptake.<\/jats:p>","DOI":"10.1371\/journal.pgph.0006293","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:29:18Z","timestamp":1778866158000},"page":"e0006293","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interest in long-acting injectable ART among adolescents with perinatally acquired HIV in Cameroon: Implications for implementation in developing countries"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-683X","authenticated-orcid":true,"given":"Yagai","family":"Bouba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude Christelle","family":"Ka\u2019e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Ayafor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lum","family":"Forgwei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah Efakika","family":"Gabisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3337-766X","authenticated-orcid":true,"given":"Daniel","family":"Mabongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita Ekwoge","family":"Mejane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzie Ndiang","family":"Tetang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel Simo","family":"Kamgaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis Ndongo","family":"Ateba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine Nguendjoung","family":"Fainguem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Carlos Tommo","family":"Tchouaket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desire","family":"Takou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-5732","authenticated-orcid":true,"given":"Nelly","family":"Kamgaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Aloum","family":"Menye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9licit\u00e9","family":"Noukayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-2371","authenticated-orcid":true,"given":"Ezechiel Ngoufack Jagni","family":"Semengue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland Wome","family":"Basseck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agabus","family":"Wiadamong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdou Rahamani","family":"Gnambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Eyenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi-Karell","family":"Etame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-5730","authenticated-orcid":true,"given":"Aurelie Minelle Kengni","family":"Ngueko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Ga\u00eblle Moko","family":"Fotso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junie Flore","family":"Yimga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Anong","family":"Beloumou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collins Ambe","family":"Chenwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Martin","family":"Sosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Ketchaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-3845","authenticated-orcid":true,"given":"Hyppolite Kuekou","family":"Tchidjou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Edie Halle","family":"Ekane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Ndombo","family":"Koki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-8580","authenticated-orcid":true,"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogers Awoh","family":"Ajeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"D\u2019amelio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"pgph.0006293.ref001","unstructured":"Joint United Nations Programme on HIV\/AIDS. Global HIV & AIDS statistics \u2014 Fact sheet. 2024. [cited 2025 Apr 29]. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"pgph.0006293.ref002","unstructured":"National AIDS Control Committee (NACC). Annual report of HIV response activities 2023. [cited 2025 Apr 30]. Available from: http:\/\/www.cnls.cm\/uploads\/docs\/2025-01-02-rapport-annuel-2023-vih-draft-final-latest.pdf"},{"key":"pgph.0006293.ref003","unstructured":"World Health Organization. Recommends dolutegravir as preferred HIV treatment option in all populations. 2019. [cited 2025 Apr 30]. Available from: https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations"},{"key":"pgph.0006293.ref004","unstructured":"Joint United Nations Programme on HIV\/AIDS. Understanding measures of progress towards the 95\u201395\u201395 HIV testing, treatment and viral suppression targets. 2024. [cited 2025 Apr 30]. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/progress-towards-95-95-95"},{"issue":"20","key":"pgph.0006293.ref005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033737","article-title":"Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: children at high risk of virological failure due to the lowly transition in pediatrics","volume":"102","author":"J Fokam","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"pgph.0006293.ref006","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/QAD.0000000000000316","article-title":"Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis","volume":"28","author":"S-H Kim","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"pgph.0006293.ref007","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1086\/313849","article-title":"Factors affecting adherence to antiretroviral therapy","volume":"30","author":"MA Chesney","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pgph.0006293.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00301-6","article-title":"Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017\/MOCHA): a secondary analysis of a phase 1\/2, multicentre, open-label, non-comparative dose-finding study","volume":"11","author":"ED Lowenthal","year":"2024","journal-title":"Lancet HIV"},{"issue":"3","key":"pgph.0006293.ref009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/COH.0000000000000732","article-title":"Implementation of long-acting antiretroviral therapy in low-income and middle-income countries","volume":"17","author":"FV Cresswell","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"pgph.0006293.ref010","unstructured":"US. Food and Drug Administration. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. FDA. 2021. [cited 2025 Apr 30]. Available from: https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection"},{"issue":"7","key":"pgph.0006293.ref011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/INF.0000000000004742","article-title":"Efficacy, Safety and retention in care among adolescents and youth with HIV on long-acting injectable cabotegravir\/rilpivirine treatment: real-world observational cohort outcomes","volume":"44","author":"T Williams","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"pgph.0006293.ref012","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12879-025-10871-0","article-title":"Bridging the gap: identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: a scoping review","volume":"25","author":"P Gashema","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pgph.0006293.ref013","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1186\/s12879-024-09748-5","article-title":"Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda","volume":"24","author":"H Zakumumpa","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"6","key":"pgph.0006293.ref014","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/apc.2023.0017","article-title":"High acceptability and perceived feasibility of long-acting injectable antiretroviral treatment among people living with HIV who are viremic and health workers in Uganda","volume":"37","author":"CE Kennedy","year":"2023","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"pgph.0006293.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(24)00039-0","article-title":"Are we ready for long-acting HIV treatment for adolescents?","volume":"11","author":"N Rakhmanina","year":"2024","journal-title":"Lancet HIV"},{"key":"pgph.0006293.ref016","unstructured":"HIV & Adolescence Workshop 2023 - Young People\u2019s Lusaka Declaration | AME. [cited 2025 Apr 30]. Available from: https:\/\/academicmedicaleducation.com\/node\/16872"},{"issue":"9","key":"pgph.0006293.ref017","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","article-title":"Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077","volume":"24","author":"EE Tolley","year":"2020","journal-title":"AIDS Behav"},{"issue":"4","key":"pgph.0006293.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(24)00310-2","article-title":"Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial","volume":"12","author":"L Stranix-Chibanda","year":"2025","journal-title":"Lancet HIV"},{"key":"pgph.0006293.ref019","article-title":"The injection gives freedom - An exploration of long-acting injectable HIV treatment acceptance among patients seeking care in two Nairobi tertiary hospitals","author":"ND Wekesa","year":"2025","journal-title":"medRxiv"},{"issue":"10","key":"pgph.0006293.ref020","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s10461-024-04423-x","article-title":"Engagement in care, awareness, and interest in long-acting injectable anti-retroviral therapy","volume":"28","author":"JA Stout","year":"2024","journal-title":"AIDS Behav"},{"key":"pgph.0006293.ref021","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac716","article-title":"Barriers to Uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries","volume":"75","author":"SE Cooper","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pgph.0006293.ref022","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"C Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pgph.0006293.ref023","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/COH.0000000000000449","article-title":"The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes","volume":"13","author":"AL Slogrove","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"8","key":"pgph.0006293.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002636","article-title":"Understanding preferences for HIV care and treatment in Zambia: evidence from a discrete choice experiment among patients who have been lost to follow-up","volume":"15","author":"A Zanolini","year":"2018","journal-title":"PLoS Med"},{"issue":"20","key":"pgph.0006293.ref025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000042555","article-title":"Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: evidence from a cohort analysis in Cameroon","volume":"104","author":"Y Bouba","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"pgph.0006293.ref026","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3390\/biomedicines12092083","article-title":"Evaluation of viral suppression in paediatric populations: implications for the transition to dolutegravir-based regimens in Cameroon: The CIPHER-ADOLA Study","volume":"12","author":"J Fokam","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"pgph.0006293.ref027","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/v16121853","article-title":"Predictive efficacy of dual therapies combining integrase strand transfer inhibitors with second-generation non-nucleoside reverse transcriptase inhibitors following HIV-1 treatment failure in Cameroon: implications for the use of a long-acting therapeutic strategy in low- and middle-income countries","volume":"16","author":"D-H Gouissi Anguechia","year":"2024","journal-title":"Viruses"},{"key":"pgph.0006293.ref028","unstructured":"Cameroon National AIDS Control Committee. Directives nationales sur la prise en charge du VIH. 2021. [cited 2025 Apr 30]. Available from: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/Directives_version-finale-05-aout-2021_Cameroon.pdf"},{"key":"pgph.0006293.ref029","unstructured":"Centers for Disease Control and Prevention. Child and Teen BMI Categories. 2024. [cited 2025 Apr 30]. Available from: https:\/\/www.cdc.gov\/bmi\/child-teen-calculator\/bmi-categories.html"},{"key":"pgph.0006293.ref030","unstructured":"World Health Organization. What\u2019s new in treatment monitoring: viral load and CD4 testing. 2017. [cited 2025 Apr 30]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2017.22"},{"key":"pgph.0006293.ref031","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. [cited 2025 Apr 30]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"key":"pgph.0006293.ref032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Z Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"issue":"7","key":"pgph.0006293.ref033","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/apc.2024.0076","article-title":"\u201cI Feel Like I Don\u2019t Even Have HIV Anymore\u201d-facilitators, barriers, and experience regarding use of long-acting injectable antiretroviral therapy among persons with HIV in North Carolina","volume":"38","author":"H Agarwal","year":"2024","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"pgph.0006293.ref034","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(13)70363-3","article-title":"Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges","volume":"14","author":"ED Lowenthal","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"pgph.0006293.ref035","unstructured":"World Health Organisation. Guideline on HIV disclosure counselling for children up to 12 years of age. 2025. [cited 2025 Apr 30]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241502863"},{"issue":"8","key":"pgph.0006293.ref036","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"B Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"},{"issue":"6","key":"pgph.0006293.ref037","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M","volume":"14","author":"V Chounta","year":"2021","journal-title":"). The Patient"},{"issue":"2","key":"pgph.0006293.ref038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1310\/hpj5202-124","article-title":"Pharmacists and pediatric medication adherence: bridging the gap","volume":"52","author":"S El-Rachidi","year":"2017","journal-title":"Hosp Pharm"},{"issue":"3","key":"pgph.0006293.ref039","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","article-title":"Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study","volume":"25","author":"P de Los Rios","year":"2021","journal-title":"AIDS Behav"},{"issue":"1","key":"pgph.0006293.ref040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy","volume":"78","author":"JB Brock","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:29:25Z","timestamp":1778866165000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006293"}},"subtitle":[],"editor":[{"given":"Henry","family":"Zakumumpa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0006293","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}